Clinical Trial Update: A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ALN-KHK in overweight/obese adults, including obese patients with Type 2 Diabetes Mellitus, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• ALN-KHK

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Type 2 Diabetes Mellitus (T2DM) | Phase 1, Phase 2 | Status: TERMINATED